# Olanzapine

## Okpine F.C. 5mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OOKP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 適應症     | Treatment of the manifestations of schizophrenia; treatment of acute or mixed mania episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or valproate); maintenance treatment of bipolar I disorder; in combination with fluoxetine for treatment-resistant or bipolar I depression.                                                                                                                                                                                                                                                                                                                                                                                                  |
| 用法用量   | Schizophrenia: Oral: Initial: 5 to 10 mg once daily (increase to 10 mg once daily within 5 to 7 days) Bipolar I: Oral: Monotherapy: Initial: 10 to 15 mg once daily; increase by 5 mg daily at intervals of not less than 24 hours. Maintenance: 5 to 20 mg daily; recommended maximum dose: 20 mg daily.                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 禁忌       | Hypersensitivity to olanzapine or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 副作用     | >10%: Cardiovascular: Orthostatic hypotension (3-20%) Central nervous system: Drowsiness(20-39%), extrapyramidal reaction (10-32%), akathisia (3-27%), parkinsonian-like syndrome (14% to 20%), dizziness (8-11%), headache (adolescents 17%), fatigue (2% to 14%), insomnia (12%) Endocrine & metabolic: Increased serum prolactin (30-47%), weight gain (5-40%) Gastrointestinal: Increased appetite (3-29%), xerostomia (3-22%), dyspepsia (3-11%), constipation (4-11%) Hepatic: Increased serum AST (adolescents 28%), decreased serum bilirubin (adolescents 22%), increased serum ALT (?3 x ULN; adolescents and adults 5% to 12%) Neuromuscular & skeletal: Weakness (8-20%) Miscellaneous: Accidental injury (12%) |
| 孕期建議   | Compatible – maternal benefit >> embryo-fetal risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

